MyAverix Finance
SHG · Healthcare
Cabio Biotech Wuhan Co Ltd (688089)
Biotechnology
Cabio Biotech Wuhan Co Ltd (688089) is listed on SHG in the Healthcare sector. Industry: Biotechnology. As of 2026-03-29, reported market cap is $3.07B, P/E ratio is 18.06, net margin is 27.3%. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.
Key metrics for 688089
Cabio Biotech Wuhan Co Ltd (688089) — FAQ
What is Cabio Biotech Wuhan Co Ltd's market cap?
Cabio Biotech Wuhan Co Ltd (688089) has a reported market cap of $3.07B (data as of 2026-03-29).
What is 688089's P/E ratio?
The price-to-earnings (P/E) ratio for Cabio Biotech Wuhan Co Ltd (688089) is 18.06 (data as of 2026-03-29).
Does Cabio Biotech Wuhan Co Ltd pay a dividend?
Dividend yield is not available in the current snapshot for Cabio Biotech Wuhan Co Ltd (688089). Check the MyAverix Finance app for the latest dividend data.
What sector is Cabio Biotech Wuhan Co Ltd in?
Cabio Biotech Wuhan Co Ltd (688089) is classified in the Healthcare sector (Biotechnology industry).
What exchange is 688089 listed on?
688089 is listed on SHG.
What is Cabio Biotech Wuhan Co Ltd's net margin?
Cabio Biotech Wuhan Co Ltd (688089) reports a net margin of 27.3% (data as of 2026-03-29).
Full report in the app
Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.